UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 408

Sortiert nach

Pharmacokinetic pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

Leukemia, 2009-09, Vol.23 (9), p.1537-1544

2009

Volltextzugriff (PDF)

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis

Annals of oncology, 2013-04, Vol.24 (4), p.1112-1119

2013

Volltextzugriff (PDF)

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

British journal of cancer, 2012-08, Vol.107 (4), p.592-597

2012

Volltextzugriff (PDF)

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

Journal of clinical oncology, 1995-01, Vol.13 (1), p.180-190

1995

Volltextzugriff (PDF)

Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

Journal of Perinatology, 2007-04, Vol.27 (4), p.241-243

2007

Volltextzugriff (PDF)

High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1561-1567

1998

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565

Journal of clinical oncology, 2000-07, Vol.18 (14), p.2780-2787

2000

Volltextzugriff (PDF)

Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies

European journal of cancer (1990), 2002-01, Vol.38 (1), p.11-16

2002

Volltextzugriff (PDF)

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

Clinical cancer research, 1998-03, Vol.4 (3), p.629-634

1998

Volltextzugriff (PDF)

Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone

Annals of oncology, 2007-01, Vol.18 (1), p.190-195

2007

Volltextzugriff (PDF)

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264

Journal of clinical oncology, 1998-05, Vol.16 (5), p.1811-1819

1998

Volltextzugriff (PDF)

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

Journal of clinical oncology, 1992-04, Vol.10 (4), p.520-528

1992

Volltextzugriff (PDF)

Delayed Administration of Sodium Thiosulfate in Animal Models Reduces Platinum Ototoxicity without Reduction of Antitumor Activity

Clinical cancer research, 2000-01, Vol.6 (1), p.309-315

2000

Volltextzugriff (PDF)

Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations

Cancer research (Chicago, Ill.), 1998-06, Vol.58 (11), p.2385-2396

1998

Volltextzugriff (PDF)

Paclitaxel pharmacokinetics and pharmacodynamics

Seminars in oncology, 1995-06, Vol.22 (3), p.16-23

1995

Volltextzugriff (PDF)

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

Journal of clinical oncology, 2000-03, Vol.18 (5), p.1124-1134

2000

Volltextzugriff (PDF)

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.676-684

1999

Volltextzugriff (PDF)

Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats

Cancer chemotherapy and pharmacology, 1999, Vol.43 (6), p.445-453

1999

Volltextzugriff (PDF)

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

Journal of clinical oncology, 1995-12, Vol.13 (12), p.2944-2953

1995

Volltextzugriff (PDF)

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

JNCI : Journal of the National Cancer Institute, 1993-04, Vol.85 (8), p.611-621

1993

Volltextzugriff (PDF)

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck

International journal of radiation oncology, biology, physics, 2000-04, Vol.47 (1), p.49-56

2000

Volltextzugriff (PDF)

Paclitaxel Disposition in Plasma and Central Nervous Systems of Humans and Rats With Brain Tumors

JNCI : Journal of the National Cancer Institute, 1995-07, Vol.87 (14), p.1077-1081

1995

Volltextzugriff (PDF)

The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid

Annals of oncology, 2001-01, Vol.12 (1), p.119-122

2001

Volltextzugriff (PDF)

Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion

Thyroid (New York, N.Y.), 2000-07, Vol.10 (7), p.587-594

2000

Volltextzugriff (PDF)

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas

Journal of clinical oncology, 1996-02, Vol.14 (2), p.600-609

1996

Volltextzugriff (PDF)

1 – 25 von 408

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(387)
Mit Volltextzugriff
(360)

Publikationsform

Artikel
(408)

Sprache

Englisch
(408)
Japanisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565

Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

Delayed Administration of Sodium Thiosulfate in Animal Models Reduces Platinum Ototoxicity without Reduction of Antitumor Activity

Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations

Paclitaxel pharmacokinetics and pharmacodynamics

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer

Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck

Paclitaxel Disposition in Plasma and Central Nervous Systems of Humans and Rats With Brain Tumors

The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid

Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas

Suchergebnisse filtern